Sweden-based Cantargia has commenced an expanded segment of the ongoing Phase I trial of its antibody, CAN10, with the first participant currently dosed.
This expansion is aimed at building on the pharmacokinetic properties, observed safety, and biomarker effects of the antibody.
Go deeper with GlobalData
CAN10 is designed to inhibit the pro-inflammatory cytokines IL-1, IL-33, and IL-36 through its action on the interleukin-1 receptor accessory protein (IL-1RAP).
The phase I trial’s primary objective is to assess the safety of CAN10. So far, this trial has reported no safety concerns and biomarker studies showed that the antibody can completely inhibit IL-1 and IL-36 stimulation.
The trial has involved nine single-ascending dose (SAD) cohorts and one multiple-ascending dose (MAD) cohort so far with subjects having mild to moderate plaque psoriasis.
Findings suggest that the therapy has long-lasting effects, potentially offering a four-week dosing schedule.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTo further investigate this potential, up to two additional SAD cohorts and two additional MAD cohorts were included in healthy subjects as per the amendment of the clinical protocol.
These activities are planned for the coming months, aligning to commence Phase II in the second half of 2025.
Cantargia CEO Göran Forsberg said: “The accrued CAN10 clinical results underscore the potential for dosing every fourth week.”
The primary focus of the antibody will be on treating hidradenitis suppurativa (HS) and systemic sclerosis, conditions with significant unmet medical needs.
Preclinical in vivo models have shown that a surrogate antibody of CAN10 decreased disease development in several inflammatory conditions such as psoriasis, systemic sclerosis, psoriatic arthritis, peritonitis, atherosclerosis, and myocarditis.
In January 2023, the company completed the Good Laboratory Practice (GLP) toxicity study of CAN10.
The company is also advancing its oncology programme with the antibody nadunolimab (CAN04), which is undergoing clinical trials with chemotherapy combinations for several cancers.
Unlike nadunolimab, CAN10 claims to block signalling via IL1RAP differently, targeting inflammatory and autoimmune conditions.
